Exact Sciences Reports Strong Growth Trajectory for Cologuard™ in First-Quarter 2015
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Lake Street Capital Markets Downgrades Exact Sciences (EXAS) to Hold
May 5, 2015 9:22 AM EDTLake Street Capital Markets downgraded Exact Sciences (NASDAQ: EXAS) from Buy to Hold with a price target of $24.00 (from $28.00). The change follows Q1 results, which were described as slightly better than expected. Analyst Bruce D. Jackson said Cologuard unit ramp and commercial pricing... More
Exact Sciences (EXAS) Tops Q1 EPS by 1c, Company Pleased with Launch Trajectory of Cologuard
May 4, 2015 8:56 AM EDTExact Sciences (NASDAQ: EXAS) reported Q1 EPS of ($0.40), $0.01 better than the analyst estimate of ($0.41). Revenue for the quarter came in at $4.3 million versus the consensus estimate of $4.11 million.
11,000 Cologuard tests were completed and the number of ordering physicians more than doubled,... More
